JP Morgan Chase
ORIC icon

JP Morgan Chase’s Oric Pharmaceuticals ORIC Stock Holding History

JP Morgan Chase’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-13,500
Closed -$81.7K – 7775
2023
Q3 		$81.7K Buy
+13,500
New +$111K ﹤0.01% 5606

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

JP Morgan Chase's ORIC Position: Q1 2026 in Review

JP Morgan Chase reduced its Oric Pharmaceuticals (ORIC) stake by 22% in Q1 2026, selling an estimated $1.04M and leaving 323,584 shares worth $3.94M. The position accounts for ﹤0.01% of the portfolio, ranked #3544.

JP Morgan Chase first reported a position in ORIC in Q2 2020 and has held it in 24 quarters since. The position peaked at $14.7M in Q3 2025. 182 funds tracked by Wall St. Rank hold ORIC as of Q1 2026.

  • JP Morgan Chase held 323,584 shares of Oric Pharmaceuticals worth $3.94M as of Q1 2026.
  • JP Morgan Chase sold 91,202 Oric Pharmaceuticals shares in Q1 2026, an estimated $1.04M.
  • Oric Pharmaceuticals made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #3544 holding.
  • JP Morgan Chase first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Oric Pharmaceuticals position peaked at $14.7M in Q3 2025.
  • 182 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.